CalciMedica was founded in December 2006 to pursue the discovery and development of novel calcium release-activated calcium (CRAC) channel inhibitors for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The Company acquired exclusive rights to both STIM1 and Orai1, the major protein components of the CRAC channel, for its research program.
CalciMedica’s research and development efforts have resulted in the generation of a number of unique and potent CRAC channel inhibitors. CM2489, the first CRAC channel inhibitor to be tested in humans, was administered to moderate-to-severe plaque psoriasis patients in a proof-of-concept study, and shown to be safe, well tolerated and well-behaved, with evidence of clinical improvement. More potent compounds were designed, one of which, CM4620, will enter human safety studies in late Q4, 2016. It is being developed for acute pancreatitis. Severe forms of this disease are very serious, with significant morbidity and mortality, and there are currently no disease-modifying therapies available. Additional CRAC channel inhibitors are in preclinical development for other indications.
CalciMedica is privately held, and has three major investors: Sanderling Ventures, SR One and Biogen. The Company raised a Series A Preferred round of funding in 2014, following conversion of prior investments and loans into Junior Preferred Shares.
Managing Director, Sanderling Ventures
Chief Medical Officer, La Jolla Pharmaceuticals Company
Asst. Professor, NYU School of Medicine
Member, La Jolla Institute for Allergy and
Professor, Harvard Medical School
Head and Member, La Jolla Institute for Allergy
Member of National Academy of Sciences
Professor of Medicine, UCLA, Director of Basic and Translational Pancreas Research, Cedars-Sinai Medical Center, Los Angeles, CA